miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma

Digestive Diseases and Sciences

Volumn 56, Issue 6, 2011, Pages 1693-1701

  Chen, Yongjun ^a   Luo, Jian ^a   Tian, Rui ^a   Sun, Huawen ^b   Zou, Shengquan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

DNA methylation; Hilar cholangiocarcinoma; MBD2; miR 373; RASSF1A

Indexed keywords

MESSENGER RNA; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 1; METHYL CPG BINDING PROTEIN 2; MICRORNA; MIR 373; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE CONSTRUCT; GENETIC ANALYSIS; HILAR CHOLANGIOCARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR GENE; REPORTER GENE; RNA ANALYSIS; SURVIVAL TIME; UPREGULATION; WESTERN BLOTTING;

DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KLATSKIN'S TUMOR; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEINS;

EID: 79959721605     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1481-1     Document Type: Article

References (35)

1. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the portal hepatic. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241-256.
2. Akoad M, Jenkins R. Proximal biliary malignancy. Surg Clin North Am. 2008;88(6):1409-1428.
3. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-517.
4. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009;15(34):4240-4262.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
7. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92-105.
8. Lim LP, Lau NC, Weinstein EG, et al. The microRNAs of Caenorhabditis elegans. Genes Dev. 2003;17:991-1008. (Pubitemid 36459452)
9. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
10. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828-833. (Pubitemid 40839734)
11. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes. 1988;2:1136-1143.
12. Bird AP, Wolffe AP. Methylation-induced repression - belts, braces, and chromatin. Cell. 1999;99:451-454. (Pubitemid 129746827)
13. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature. 1999;401:301-304.
14. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997;88(4):471-481. (Pubitemid 27154412)
15. Fujita N, Takebayashi S, Okumura K, et al. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol Cell Biol. 1999;19:6415-6426. (Pubitemid 29399345)
16. Ng HH, Zhang Y, Hendrich B, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999;23:58-61. (Pubitemid 29418788)
17. Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem. 2002;277:35434-35439.
18. Li C, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009;11:747-757.
19. Jean-Pierre J. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13:1634-1637.
20. Wu L, Zhou H, Zhang Q, et al. DNA methylation mediated by a microRNA pathway. Mol Cell. 2010;38:465-475.
21. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104:15805-15810. (Pubitemid 350035380)
22. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113:6411-6648.
23. Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113-2129. (Pubitemid 43816961)
24. Li D, Chen J, Gao Z, et al. 67-kDa laminin receptor in human bile duct carcinoma. Eur Surg Res. 2009;42:168-173.
25. Careen K, Nicole S, Ad G, et al. Role of DNA methylation and methyl-DNA binding proteins in the repression of 5-lipoxygenase promoter activity. Biochim Biophys Acta. 2010;1801:49-57.
26. Vera NS, Ekaterina AA, Tatiana TK, et al. Simultaneous downregulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer. 2010;10:75-87.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408. (Pubitemid 34164012)
28. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124:1169-1181.
29. Lee KH, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res. 2009;315:2529-2538.
30. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR- 373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10:202-210. (Pubitemid 351194050)
31. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol. 2009;2:361-369.
32. Foteini C, Florian R, Raju T, et al. Ancient animal microRNAs and the evolution of tissue identity. Nature. 2010;463:1084-1088.
33. Lai KW, Koh KX, Loh M, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer. 2010;46(8):1456-1463.
34. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315-319. (Pubitemid 30437320)
35. Chen YJ, Tang QB, Zou SQ. Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11:1333-1338.